Bausch Health’s Strategic Growth in Latin American Pharmaceuticals Through Cardiometabolic Innovation
Navigating Growth in Latin American Pharmaceuticals
In the Latin American pharmaceuticals sector, Bausch Health is strategically expanding its footprint under the leadership of Vice President Fernando Zarate. The company’s operations leverage strengths in branded generics and vitamins while venturing into high-potential segments like cardiometabolic therapeutics. Regional revenue streams heavily from Mexico at 68-70% and Colombia at 20-25%, with goals to rank among the top ten pharmaceutical firms in the region within three years via diversification and innovation. This includes launching a cardiometabolic unit with GLP-1 products and anti-obesity therapies, capitalizing on a strong presence in Central America and the Caribbean.
Cardiometabolic Breakthroughs Amid Rising Health Pressures
Cardiometabolic conditions emerge as a cornerstone for expansion in Latin American pharmaceuticals, tackling interconnected health domains and Latin America’s growing challenges, especially in Mexico where 30-35 million people grapple with obesity-related issues. Zarate stresses innovation through formulations, combinations, and delivery systems—beyond just new molecules—to rival local branded generic producers who’ve raised quality benchmarks over 15-20 years. The flagship vitamin B complex, produced in Mexico and exported across the region, holds market leadership against generics, showcasing 50 years of growth and loyalty. This strategy fuels advances in branded generics and over-the-counter offerings, securing top-three spots in multiple categories in Mexico and Central America, thanks to commercial agility and local production efficiencies.
Building Robust Infrastructure Across Borders
Bausch Health’s operational backbone in Latin America, from Mexico to Peru, including Central America, the Dominican Republic, and Puerto Rico, is supported by manufacturing in Mexico and Colombia for exports and trials. An omnichannel model drives revenue—70% from private retail, labels, and generics, 30% from public tenders like Mexico’s IMSS and ISSSTE—enabling customized launches despite stricter regulations and faster access routes. Zarate highlights a shift to global integration, with investments in talent for research, such as a study on vitamin B in diabetes patients, strengthening the cardiometabolic lineup. This setup ensures adaptability to market ups and downs, evident in partnership talks for Chile and Paraguay, aligning with a long-term outlook for governmental and economic shifts.
Shaping Health Outcomes and Economic Resilience
Fernando Zarate’s interview reveals where cardiometabolic growth could improve early detection and syndrome management, cutting long-term costs with affordable, innovative products. Emphasizing physician outreach, real-world data, and regulatory alignment, Bausch Health boosts patient access and public reimbursement, countering obesity epidemics in places like Mexico. This patient-centric model, focusing on four-to-five-year brand cultivation, mirrors trends in localized tactics, enhancing pricing power, chronic care loyalty, and sustainable access. Ultimately, these initiatives elevate healthcare in underserved areas via strong franchises and varied revenues.
